This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An International Pulmonary Embolism Registry Using EKOS (KNOCOUT PE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03426124
Recruitment Status : Completed
First Posted : February 8, 2018
Results First Posted : February 22, 2023
Last Update Posted : February 22, 2023
Sponsor:
Collaborator:
BTG International Inc.
Information provided by (Responsible Party):
Boston Scientific Corporation

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This registry is designed to understand acoustic pulse thrombolysis (APT) treatment regimens used as standard of care globally for pulmonary embolism. The registry will include individuals who have already received the APT treatment and those that will undergo APT treatment.

Condition or disease Intervention/treatment
Pulmonary Embolism and Thrombosis Device: EkoSonic Endovascular System with thrombolytic

Detailed Description:

For the prospective arm of the registry, a physician will have selected the APT procedure for the treatment of pulmonary embolism. The APT treatment and follow-up assessments are per clinical judgement and institutional standard of care which may vary at each clinical site.

For the retrospective arm of the registry, the investigators will gather data from consecutive cases of individuals who received the APT treatment for pulmonary embolism. Specific baseline, treatment, and long-term health information is collected and de-identified.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 1480 participants
Observational Model: Cohort
Time Perspective: Other
Target Follow-Up Duration: 1 Year
Official Title: Retrospective and Prospective International EkoSonic® Registry of the Treatment and Clinical OUTcomes of Patients With Pulmonary Embolism
Actual Study Start Date : March 1, 2018
Actual Primary Completion Date : June 30, 2020
Actual Study Completion Date : September 30, 2020

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Retrospective
Individuals with intermediate-high or high risk pulmonary embolism who were consecutively treated with the Ekosonic Endovascular System (EKOS) and thrombolytic drug between January 2014 and one year prior to site activation.
 Device: EkoSonic Endovascular System with thrombolytic
The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.
Other Names:
  • Acoustic Pulse Thrombolysis
  • EKOS
Prospective
Individuals who are experiencing intermediate-high or high risk pulmonary embolism where the treating investigator has selected the EKOS device and thrombolytic drug. The duration of ultrasound and volume of thrombolytic drug are selected per physician discretion.
 Device: EkoSonic Endovascular System with thrombolytic
The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.
Other Names:
  • Acoustic Pulse Thrombolysis
  • EKOS


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in RV/LV Ratio on Echocardiogram (Matched Pairs as Available) [ Time Frame: Baseline to post-procedure (end of procedure through hospital discharge up to 14 days) ]
    Difference (percent change) in the measurement of the right ventricular to left ventricular diameters (RV/LV) ratio as measured on baseline echocardiogram to post-procedure echocardiogram (24-48 hours post initiation of therapy).

  2. Frequency and Safety Outcomes of Subjects Requiring Interventions of Adjunctive Therapies Post-procedure During Hospitalization. [ Time Frame: Post-procedure hospitalization through hospital discharge up to 14 days ]
    Measured by number of subjects requiring interventions of adjunctive therapies received during post procedure hospitalization through hospital discharge up to 14 days.

  3. Number of Patients Who Underwent Interventional Therapies Prior to the APT Procedure and Experienced a Non- or Partial- Response. [ Time Frame: From date of enrollment up to or until the placement of the Ekos device, on average 48 hours. ]
    Measured by number of patients who underwent interventional therapies prior to the APT procedure and experienced a non or partial response.

  4. Number of Patients Experiencing a SAEs Related to EKOS Device and/or Procedure During First 12 Months Post-APT Procedure. [ Time Frame: From time of APT procedure through 12 months post-procedure. ]
    Number of subjects experiencing a SAE related to EKOS device and/or procedure from time of procedure through the first 12 months post-APT procedure, measured by frequency and severity of events.

  5. All-cause Mortality During First 12 Months Post-procedure. [ Time Frame: Start of procedure through 12 months post-procedure. ]
    Number of all-cause mortality that occurred from the start of procedure through 12 months post-procedure.

  6. Healthcare Utilization [ Time Frame: Measured as time from ICU admission to ICU discharge in hours (from date of enrollment through 12 months post-procedure). ]
    Summary of healthcare utilization from date of enrollment through discharge.

  7. Change in Quality of Life (QOL) as Measured by the Pulmonary Embolism Quality of Life (PEmb-QOL) at the 3 Month and 12 Month Post-hospitalization Follow-up Visits [ Time Frame: Measured as percent change in time from baseline assessment at discharge to 3 month and 12 month follow up. ]
    Reported as percent change in the PEmb-QOL questionnaire score from baseline timepoint to 3 months and 12 months. The PEmb-QOL measures patient's quality of life following pulmonary embolism on a scale of 1 through 5, with lower scores indicating a better outcome.

  8. Change in Quality of Life (QOL) as Measured by the EQ-5D-5L VAS, Utility and Misery Scores at the 3-month and 12-month Post-hospitalization Follow-up Visits. [ Time Frame: Reported results include change from baseline to 3 months and 12 months post-procedure for prospective patients. ]

    Reported as change in the VAS, Utility and Misery questionnaire scores from baseline timepoint and/or study visit to 3 months and 12 months.

    The VAS (Visual Analogue Scale) is a one question, unidimensional measure of pain intensity where a subject is asked to rate his pain on a scale of 100 through 1, with 100 indicating the best health imaginable through 1 indicating the worst health imaginable. Higher scores indicate a better outcome.

    The EQ-5D is a series of questions that measures Quality of Life on a scale of 0 through 5. 0 indicates no problems in daily activities and 5 indicates inability to perform daily activities. The total score is added up and compared to the total scale from 0 to 25, with 0 indicating no problems in daily activities and 25 indicating inability to perform daily activities. A lower score indicates a better outcome.


  9. Number of Patients Needing an IVC Filter Placement [ Time Frame: From date of procedure through 12 months ]
    Measured by number patients with an occurrence of needing an IVC filter placement.

  10. Number of Patients Experiencing Adverse Events Classified as Major Bleeding Events During First 12 Months Post-Procedure by Frequency and Severity [ Time Frame: From post-procedure through 12-months post-procedure ]
    Measured by number of patients experiencing adverse events related to major bleeding events from time of procedure through the first 12 months post-procedure by frequency and severity (mild, moderate, severe).

  11. Number of Patients Experiencing VTE (Venus Thromboembolytic Events) During First 12 Months Post-Procedure by Frequency and Severity. [ Time Frame: From post-procedure through 12-months post-procedure ]
    Number of patients experiencing events related to VTE from time of procedure through the first 12 months post-procedure by frequency and severity.

  12. Diagnosis of Pulmonary Hypertension Diagnosis [ Time Frame: Analyzed 12 months post-procedure ]
    New onset pulmonary hypertension defined as mean pulmonary artery pressure greater than 25 mm Hg by echocardiogram that persists at least 3 months after PE.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals with intermediate-high and high risk pulmonary embolism who are selected to receive treatment using the EKOS device and thrombolytic.
Criteria

Retrospective Inclusion Criteria:

  • Treated with APT procedure between January 1, 2014 and one year prior to site activation
  • RV/LV ≥ 1.0 from diagnostic computed tomographic angiography (CTA) or echocardiogram
  • PE symptom duration ≤ 14 days
  • Troponin elevation

Retrospective Exclusion Criteria:

  • Enrollment into the OPTALYSE PE study

Prospective Inclusion Criteria:

  • Male or female ≥ 18 years of age and ≤ 80 years of age
  • RV/LV ≥ 1.0 from diagnostic computed tomographic angiography (CTA) or echocardiogram
  • PE symptom duration ≤ 14 days
  • Troponin elevation
  • Signed informed consent obtained from participant or legally authorized representative
  • Investigator has selected the EKOS device to treat participant with massive or submassive pulmonary embolism

Prospective Exclusion Criteria:

  • High-risk for catastrophic bleeding
  • Life expectancy < one year
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03426124


Locations
Show Show 80 study locations
Sponsors and Collaborators
Boston Scientific Corporation
BTG International Inc.
Investigators
Layout table for investigator information
Principal Investigator: Keith Sterling, MD Inova Alexandria Hospital
  Study Documents (Full-Text)

Documents provided by Boston Scientific Corporation:
Study Protocol  [PDF] October 19, 2018
Statistical Analysis Plan  [PDF] March 1, 2019

More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT03426124    
Other Study ID Numbers: BTG-001653-01
First Posted: February 8, 2018    Key Record Dates
Results First Posted: February 22, 2023
Last Update Posted: February 22, 2023
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Boston Scientific Corporation:
venous thromboembolism
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Embolism
Thrombosis
Embolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
 Lung Diseases
Respiratory Tract Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action